Aligned Genetics KRX:238120KOSDAQ
얼라인드 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days1
DART filings, 7 days0
Articles tracked3since Sep 11
In Q2 2026, Aligned Genetics reported revenue of ₩4.4bn, up 10.9% year on year, and operating profit of ₩644m. Aligned Genetics (얼라인드) appeared in 1 Korean news article and 0 DART filings over the past seven days. Coverage peaked on Oct 29 with 1 article. The most common catalyst was contracts & orders (1).
Aligned Genetics quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩4.4bn | +10.9% | ₩644m margin 14.8% | ₩1.7bn |
| Q1 2026 | ₩3.6bn | -7.2% | ₩230m margin 6.3% | ₩418m |
| Q4 2025 derived | ₩4.3bn | -23.8% | ₩1.1bn margin 25.9% | ₩1.5bn |
| Q3 2025 | ₩3.9bn | +4.8% | ₩545m margin 14.0% | ₩933m |
| Q2 2025 | ₩3.9bn | +20.4% | ₩260m margin 6.6% | −₩117m |
| Q1 2025 | ₩3.9bn | +22.9% | ₩531m margin 13.5% | ₩554m |
| Q4 2024 derived | ₩5.6bn | +16.1% | ₩1.6bn margin 27.8% | ₩2.4bn |
| Q3 2024 | ₩3.7bn | +1.8% | ₩760m margin 20.5% | ₩507m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Aligned Genetics top stories 2 weeks, by number of outlets
- 1